Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 3/2016

01-03-2016 | Diabetes and Pregnancy (CJ Homko, Section Editor)

Myo-Inositol Supplementation to Prevent Gestational Diabetes Mellitus

Authors: Claudio Celentano, Barbara Matarrelli, Peter A. Mattei, Giulia Pavone, Ester Vitacolonna, Marco Liberati

Published in: Current Diabetes Reports | Issue 3/2016

Login to get access

Abstract

Gestational diabetes mellitus (GDM) is a common complication characterized by increased insulin resistance, and by increased risk for adverse pregnancy outcomes affecting both the mother and the fetus. International guidelines describe optimal ways to recognize it, and the recommended treatment of patients affected to reduce adverse outcomes. Improving insulin resistance could reduce incidence of GDM and its complications. Recently, a few trials have been published on the possible prevention of GDM. Inositol has been proposed as a food supplement that might reduce gestational diabetes incidence in high-risk pregnant women.
Literature
1.
Buchannan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005;115:485–91.CrossRef
2.
Corrado F, Pintaudi B, Di Vieste G, et al. Italian risk-factor based screening for gestational diabetes. J Matern Fetal Med. 2014;27:1445–8.CrossRef
3.
Ten WT, Teede HJ, Paul E, et al. Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines. Aus N Z J Obstet Gynaeocol. 2011;51:26–30.CrossRef
4.
5.•
HAPO study Cooperative research Group, Metger B, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002. The present study represents the mainstay of a new era in gestational diabetes diagnosis.CrossRef
6.
Geimlueck CJ, Panikoff J, Aregawi D, et al. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril. 2088;89:625–34.CrossRef
7.
Vanky E, Stridklev S, Heimstad R, et al. Metformine versus placebo from first trimester to delivery in plycystic ovary syndrome: a randomized controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E445–8.CrossRef
8.
Chau JFL, Lee JWS, Law SK, et al. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J. 2005;19:1887–9.PubMed
9.
Dai Z, Chung D, Miao KS, Lau AWH. Sodium/myo-inositol cotransporter-1 and myo-inositol are essential for osteogenesis and bone formation. J Bone Miner Res. 2011;26:582–90.CrossRefPubMed
10.
Carlomagno G, Unfer V, Buffo S, et al. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2011;26:526–30.CrossRef
11.
Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositl in women with PCOs: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28:569–75.CrossRef
12.
Ciotta L, Stradacquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte’s quality in PCOs patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011;15:509–14.PubMed
13.
Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011;15:452–7.PubMed
14.
Condorelli RA, La Vignera S, Di Bari F, et al. Effects of myoinositol on sperm mitochondrial function in-vitro. Eur Rev Med Pharmacol Sci. 2011;15:129–34.PubMed
15.
Condorelli RA, La Vignera S, Bellanca S, et al. Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012;79:1290–5.CrossRefPubMed
16.
Santamaria A, Giordano D, Corrado F, et al. One-year effects of myo-inositol supplementation in post-menopausal women with metabolic syndrome. Climateric. 2012;15:490–5.CrossRef
17.
Croze ML, Vella RE, Pillon NJ, et al. Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem. 2013;24:457–66.CrossRefPubMed
18.
Maeba R, Hara H, Ishikawa H, et al. Myo-inositol treatment increases serum plasmaogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol. 2008;54:196–202.CrossRefPubMed
19.
Ortmeyer HK. Dietary myoinositol in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys. Obes Res. 1996;4:569–75.CrossRefPubMed
20.••
Croze L, Soulage C. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95:1811–27. The present review represents a complete description of myo-inositol in medicine.CrossRefPubMed
21.••
Malvasi A, Casciaro F, Minervini MM, et al. Myo-inositol, D-Chiro- inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18:270–4. This is the first description of different inositol stereoisomers in pregnancy.PubMed
22.
Saltier AR. Second messenger of insulin action. Diabetes Care. 1990;13:244–56.CrossRef
23.••
Corrado F, D'Anna R, Di Vieste G. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011;28:972–5. The present study is a controlled trial in GDM treatment with myo-inositol.CrossRefPubMed
24.••
D’Anna R, Scilipoti A, Giordano D, et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes. Diabetes Care. 2013;36:854–7. This study compared myo-inositol and placebo in a high-risk population.
25.••
Matarrelli B, Vitacolonna E, D'Angelo, et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013;26:967–72. This is a controlled double-blind controlled trial.CrossRefPubMed
26.••
D’Anna R, Di Benedetto A, Scilipoti A. Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women. Obstet Gynecol. 2015;126:310–5. The study exposed obese pregnant women to myo-inositol.CrossRefPubMed
27.
Kennington AS, Hill CR, Craig J, et al. Low urinary chiro-inositol excretion in noninsulin-dependent diabetes mellitus. N Engl J Med. 1990;323:373–8.CrossRefPubMed
28.
Ortmeyer HK, Huang LC, Zhang L, et al. Chiroinositol deficiency and insulin resistance acute effects of D-Chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistance rhesus monkeys. Endocrinology. 1993;132:646.PubMed
29.
Ortmeyer HK, Huang LC, Zhang L. Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys. Obes Res. 1995;3 Suppl 4:605S–8.CrossRefPubMed
30.
Ortmeyer HK. DIetary myo-inositol results in lower urine glucose and in lower post-prandialplasma glucose in obese insulin resistant rhesus monkey. Obes Res. 1996;4:569–75.CrossRefPubMed
Metadata
Title
Myo-Inositol Supplementation to Prevent Gestational Diabetes Mellitus
Authors
Claudio Celentano
Barbara Matarrelli
Peter A. Mattei
Giulia Pavone
Ester Vitacolonna
Marco Liberati
Publication date
01-03-2016
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 3/2016
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-016-0726-6

Other articles of this Issue 3/2016

Current Diabetes Reports 3/2016 Go to the issue

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

Stress Hyperglycemia During Surgery and Anesthesia: Pathogenesis and Clinical Implications

Microvascular Complications—Nephropathy (AP Maxwell, Section Editor)

MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

The Emory University Perioperative Algorithm for the Management of Hyperglycemia and Diabetes in Non-cardiac Surgery Patients

Microvascular Complications—Nephropathy (AP Maxwell, Section Editor)

Epigenetic Mechanisms in Diabetic Kidney Disease

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

Perioperative Glycemic Control During Colorectal Surgery

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Inflammation as a Therapeutic Target for Diabetic Neuropathies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits